On the other hand, neurodegenerative injury biomarkers and cognitive symptoms are not considered as specific to AD as opposed to Aβ and pathologic tau biomarkers, which are specific neuropathological changes that define AD. This evidence concerns the gene MAPT and Alzheimer disease.